IMNN
Price
$5.75
Change
+$0.10 (+1.77%)
Updated
Sep 12 closing price
Capitalization
14.5M
65 days until earnings call
REPL
Price
$5.73
Change
-$0.28 (-4.66%)
Updated
Sep 12 closing price
Capitalization
469.12M
66 days until earnings call
Interact to see
Advertisement

IMNN vs REPL

Header iconIMNN vs REPL Comparison
Open Charts IMNN vs REPLBanner chart's image
Imunon
Price$5.75
Change+$0.10 (+1.77%)
Volume$45.07K
Capitalization14.5M
Replimune Group
Price$5.73
Change-$0.28 (-4.66%)
Volume$1.38M
Capitalization469.12M
IMNN vs REPL Comparison Chart in %
Loading...
IMNN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMNN vs. REPL commentary
Sep 13, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMNN is a Hold and REPL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 13, 2025
Stock price -- (IMNN: $5.75 vs. REPL: $5.73)
Brand notoriety: IMNN and REPL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMNN: 18% vs. REPL: 12%
Market capitalization -- IMNN: $14.5M vs. REPL: $469.12M
IMNN [@Biotechnology] is valued at $14.5M. REPL’s [@Biotechnology] market capitalization is $469.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.15B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMNN’s FA Score shows that 0 FA rating(s) are green whileREPL’s FA Score has 0 green FA rating(s).

  • IMNN’s FA Score: 0 green, 5 red.
  • REPL’s FA Score: 0 green, 5 red.
According to our system of comparison, both IMNN and REPL are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMNN’s TA Score shows that 3 TA indicator(s) are bullish while REPL’s TA Score has 4 bullish TA indicator(s).

  • IMNN’s TA Score: 3 bullish, 4 bearish.
  • REPL’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, REPL is a better buy in the short-term than IMNN.

Price Growth

IMNN (@Biotechnology) experienced а -0.09% price change this week, while REPL (@Biotechnology) price change was -9.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.38%. For the same industry, the average monthly price growth was +7.84%, and the average quarterly price growth was +35.14%.

Reported Earning Dates

IMNN is expected to report earnings on Nov 17, 2025.

REPL is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+1.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REPL($469M) has a higher market cap than IMNN($14.5M). REPL (-52.684) and IMNN (-53.596) have similar YTD gains . IMNN has higher annual earnings (EBITDA): -14.79M vs. REPL (-268.18M). REPL has more cash in the bank: 403M vs. IMNN (4.73M). IMNN has less debt than REPL: IMNN (1.19M) vs REPL (76.3M). IMNN (0) and REPL (0) have equivalent revenues.
IMNNREPLIMNN / REPL
Capitalization14.5M469M3%
EBITDA-14.79M-268.18M6%
Gain YTD-53.596-52.684102%
P/E RatioN/AN/A-
Revenue00-
Total Cash4.73M403M1%
Total Debt1.19M76.3M2%
FUNDAMENTALS RATINGS
IMNN vs REPL: Fundamental Ratings
IMNN
REPL
OUTLOOK RATING
1..100
273
VALUATION
overvalued / fair valued / undervalued
1..100
50
Fair valued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
5050
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMNN's Valuation (50) in the Medical Specialties industry is in the same range as REPL (50) in the Biotechnology industry. This means that IMNN’s stock grew similarly to REPL’s over the last 12 months.

IMNN's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as REPL (100) in the Biotechnology industry. This means that IMNN’s stock grew similarly to REPL’s over the last 12 months.

REPL's SMR Rating (98) in the Biotechnology industry is in the same range as IMNN (100) in the Medical Specialties industry. This means that REPL’s stock grew similarly to IMNN’s over the last 12 months.

REPL's Price Growth Rating (50) in the Biotechnology industry is in the same range as IMNN (50) in the Medical Specialties industry. This means that REPL’s stock grew similarly to IMNN’s over the last 12 months.

REPL's P/E Growth Rating (100) in the Biotechnology industry is in the same range as IMNN (100) in the Medical Specialties industry. This means that REPL’s stock grew similarly to IMNN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IMNNREPL
RSI
ODDS (%)
Bullish Trend 1 day ago
71%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
84%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
N/A
Bullish Trend 1 day ago
75%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 3 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
89%
Bearish Trend 5 days ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 1 day ago
86%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
IMNN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
REPL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
EVSRX27.42N/A
N/A
Allspring Disciplined US Core R6
AQGRX13.29N/A
N/A
AQR Global Equity R6
FLIAX10.47N/A
N/A
First Sentier American Listed Infras Ins
CGAEX13.11N/A
N/A
Calvert Global Energy Solutions A
FMILX67.70N/A
N/A
Fidelity New Millennium

IMNN and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMNN has been loosely correlated with ABVX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNN jumps, then ABVX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMNN
1D Price
Change %
IMNN100%
+1.77%
ABVX - IMNN
58%
Loosely correlated
-2.27%
REPL - IMNN
57%
Loosely correlated
-4.66%
MRUS - IMNN
35%
Loosely correlated
-0.32%
CLSD - IMNN
30%
Poorly correlated
-8.61%
STOK - IMNN
30%
Poorly correlated
-1.76%
More

REPL and

Correlation & Price change

A.I.dvisor indicates that over the last year, REPL has been loosely correlated with NEVPF. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if REPL jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REPL
1D Price
Change %
REPL100%
-4.66%
NEVPF - REPL
64%
Loosely correlated
N/A
ELVAF - REPL
60%
Loosely correlated
N/A
IMNN - REPL
57%
Loosely correlated
+1.77%
SNDX - REPL
49%
Loosely correlated
-5.01%
KYMR - REPL
45%
Loosely correlated
+1.71%
More